- Prostate Cancer and Prostatic Diseases
Journal: Prostate Cancer and Prostatic Diseases
From the Editor
From the Desk of the Associate Editor: PSMA PET/CT in the Assessment of Intra-Prostatic Prostate Cancer
A large number of studies on 68Ga PSMA PET/CT are coming out of Australia due to the ready access to this technology. To give some background, PET/CT imaging has long been registered with the Australian Therapeutic Goods Administration (TGA) and with this has come the approval to use any radionuclide tracer. With it being unnecessary to apply for additional registration to use new tracers, this has allowed uptake of 68Ga PSMA PET/CT into routine clinical practice throughout Australia and to the extent that it is rapidly replacing conventional radionuclide bone scans and CT scan of the abdomen and pelvis as imaging for the staging of prostate cancer.
Stephen J. Freedland, MD
Stephen J. Freedland, MD, is director of the Center for Integrated Research in Cancer and Lifestyle and co-director of the Cancer Genetics and Prevention Program and Associate Director for Faculty Development at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute. He is also a faculty physician in the Division of Urology within the Department of Surgery at Cedars-Sinai. He has served on numerous American Urological Association guideline panels for prostate cancer and co-chaired a prostate cancer guideline panel for the American Society of Clinical Oncology.
Dr. Freedland's clinical area of expertise focuses on urological diseases, particularly benign prostatic hyperplasia and prostate cancer. His approach toward cancer prevention and awareness focuses on treating the whole patient, not just the disease, by combining traditional Western medicine with complementary holistic interventions. His research interests include investigations on urological diseases and the role of diet, lifestyle and obesity in prostate cancer development and progression, as well as prostate cancer among racial groups and risk stratification for men with prostate cancer.
PCAN: June 2018
Periprostatic Adipose Inflammation is Associated with High-Grade Prostate Cancer - Full Text ArticleBackground: Obesity, a cause of subclinical inflammation, is associated with increased risk of high-grade prostate cancer (PC) and poor outcomes. Whether inflammation occurs in periprostatic white adipose tissue (WAT), and contributes to the negative impact of obesity on PC aggressiveness, is unknown.
Methods: In a single-center, cross-sectional design, men with newly diagnosed PC undergoing radical prostatectomy were eligible for study participation. The primary objective was to examine the prevalence of periprostatic WAT inflammation defined by the presence of crown-like structures (CLS-P) as detected by CD68 immunohistochemistry. Secondary objectives
PCAN: May 2018
Post Prostatectomy Outcomes of Patients with High-risk Prostate Cancer Treated with Neoadjuvant Androgen Blockade - Full Text ArticleBackground: Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease.
Methods: In this analysis, we report on the post-RP outcomes of a subset of patients enrolled in these studies. We conducted a pooled analysis of patients with available follow-up data treated on three neoadjuvant trials at three institutions. All patients received intense ADT prior to RP. The primary endpoint
PCAN: April 2018
Utilization of Biopsy-Based Genomic Classifier to Predict Distant Metastasis after Definitive Radiation and Short-Course ADT - Full Text ArticleBACKGROUND: We examined the ability of a biopsy-based 22-marker genomic classifier (GC) to predict for distant metastases after radiation and a median of 6 months of androgen deprivation therapy (ADT).
METHODS: We studied 100 patients with intermediate-risk (55%) and high-risk (45%) prostate cancer who received definitive radiation plus a median of 6 months of ADT (range 3–39 months) from 2001–2013 at a single center and had available biopsy tissue. Six to ten 4 micron sections of the needle biopsy core with the highest Gleason score and percentage of tumor involvement were
PCAN: February 2018
Prostate Cancer Radiation and Urethral Strictures: A Systematic Review and Meta-analysis - Full Text ArticleBACKGROUND: We performed a systematic review and meta-analysis to determine the prevalence and predictors of urethral stricture development post radiation therapy (RT) for prostate cancer (PCa).
METHODS: Published articles in PubMed/Medline, Cochrane, and Embase databases from January 2000 to April 2016 were queried. Inclusion criteria were any study that reported the prevalence of urethral strictures
PCAN: January 2018
Saturated Fat Intake and Prostate Cancer Aggressiveness: Results from the Population-based North Carolina-Louisiana Prostate Cancer Project - Full Text ArticleBACKGROUND:
Epidemiological and laboratory evidence supports a role for cholesterol in prostate cancer (PC). Dietary saturated fat content impacts serum cholesterol levels. However, epidemiological associations between saturated fat and PC aggressiveness are inconsistent. We hypothesized that high saturated fat intake would be associated with increased PC aggressiveness, and that statin use would modify this association.
1-6 of 15 Next